IPMAR

IPSC Platform to Model Alzheimer's Disease Risk

Certificate of analysis

DRICUi055-A

Operators: C Bridge/J Winston/O'Donoghue

Date: 04/06/2026

Supervisor: H Hall-Roberts

Date: 19/06/2026

Signature: 

Source of cells and reprogramming information

- ADCAR20352CA T cells from Cardiff 16/05/23
- Reprogrammed at UOXF AKA IPMAR62
- Reprogrammed on 05/2023 Sally Cowley/ Sarah Ellwood (Oxford)
- Reprogramming system Cytotune v2
- Clone DRICUi055-A = IPMAR62A10
- Banked at P12, 20/05/25, Rachel O'Donoghue and Jincy Winston (Cardiff)

Viability post-thaw and Morphology according to JMSCFSOP19 passage 13

- Vial cell count immediately post-thaw 1.77 x 10^6
- Viability immediately post-thaw 86.9%
- Photo at day 2 post-thaw (scale bar = 100µm):

Day 2 post-thaw, 20% plated to 1w.6wp



Sendai Cytotune 2 clearance: according to Cytotune manual Virus undetectable at passage 10



Product sizes: SeV 181bp; KOS 528bp; SeV-Klf 410bp; SeV-Myc 532bp; Actin 623bp

Sterility:

Mycoplasma test performed by Eurofins Genomics on 10/03/26, undetectable at passage 14.

Visual inspection of thawed cells cultured without antibiotic/antimycotic for 4 days:
no evidence of bacteria, yeast or fungus.

Flow cytometric analysis according to JMSCFSOP05 passage 14





Illumina GSA SNP analysis according to JMSCFSOP16

- Passage 12
- Identity to parent PBMC confirmed
- Karyotype abnormalities:
  - No gross abnormalities detected vs PBMC

Alignment of ADCAR20352CA PBMC SNPs with DRICUi055-A



Regression Coefficient R^2 : 0.9912

Karyogram ADCAR20352CA PBMC



Karyogram DRICUi055-A